Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $62.8 million versus the consensus estimate of $60.91 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.